Increased serum soluble OX40 in patients with systemic sclerosis

Kazuhiro Komura, Ayumi Yoshizaki, Masanari Kodera, Yohei Iwata, Fumihide Ogawa, Kazuhiro Shimizu, Takamasa Wayaku, Toru Yukami, Maki Murata, Minoru Hasegawa, Manabu Fujimoto, Kazuhiko Takehara, Shinichi Sato

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)


Objective. To determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSc). Methods. Serum soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals. Results. OX40 levels were significantly elevated in SSc patients (125.7 ± 5.7 pg/ml) compared to patients with SLE (80.7 ± 1.7 pg/ml; p < 0.005) and controls (88.2 ± 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05). Conclusion. Our results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease.

Original languageEnglish
Pages (from-to)2359-2362
Number of pages4
JournalJournal of Rheumatology
Issue number12
Publication statusPublished - 12-2008
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Increased serum soluble OX40 in patients with systemic sclerosis'. Together they form a unique fingerprint.

Cite this